{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:54Z","timestamp":1790315094087,"version":"4.1.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bone disease is a hallmark of multiple myeloma (MM). Occurring in the majority of MM patients, it is associated with bone pain, fractures, and hypercalcemia and has major impacts on quality of life. Furthermore, bone resorption activity has been shown to be an independent risk factor for overall survival in patients with symptomatic MM. Myeloma is characterized by a unique form of bone disease with lytic bone destruction that is not followed by reactive bone formation (uncoupling). This review focuses on recent advances in our understanding of the biology of osteoclast activation and osteoblast inhibition in MM, diagnostic standards, and recent progress in treatment options for myeloma bone disease. Translational research has enabled a rapid transfer of mechanistic insights from the bench to the bedside and will hopefully result in better treatment options and outcome for patients in near future.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0003","type":"journal-article","created":{"date-parts":[[2009,3,14]],"date-time":"2009-03-14T00:39:42Z","timestamp":1236991182000},"page":"276-283","source":"Crossref","is-referenced-by-count":61,"title":["Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment"],"prefix":"10.1093","volume":"14","author":[{"given":"Orhan","family":"Sezer","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,3,13]]},"reference":[{"issue":"suppl 2","key":"2021122207503116000_R1","doi-asserted-by":"crossref","first-page":"ii106","DOI":"10.1093\/annonc\/mdi717","article-title":"Advances in biology and treatment of multiple myeloma","volume":"16","author":"Ludwig","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122207503116000_R2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2004.04851.x","article-title":"Treatment advances in multiple myeloma","volume":"125","author":"Tricot","year":"2004","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"Ludwig","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122207503116000_R4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2021122207503116000_R6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122207503116000_R7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/leu.2008.159","article-title":"Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma","volume":"22","author":"Jakob","year":"2008","journal-title":"Leukemia"},{"key":"2021122207503116000_R8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2021122207503116000_R9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1999.01194.x","article-title":"Economic impact of using clodronate in the management of patients with multiple myeloma","volume":"104","author":"Bruce","year":"1999","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"2021122207503116000_R11","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: Myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"2021122207503116000_R12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.yexcr.2007.10.021","article-title":"Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)","volume":"314","author":"Hecht","year":"2008","journal-title":"Exp Cell Res"},{"key":"2021122207503116000_R14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"2021122207503116000_R15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"2021122207503116000_R16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"2021122207503116000_R17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"2021122207503116000_R18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2021122207503116000_R19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"2021122207503116000_R20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2021122207503116000_R21","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207503116000_R22","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"2021122207503116000_R23","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"2021122207503116000_R24","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"2021122207503116000_R25","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122207503116000_R26","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"2021122207503116000_R27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"2021122207503116000_R28","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"2021122207503116000_R29","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"2021122207503116000_R30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"2021122207503116000_R31","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"2021122207503116000_R32","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"2021122207503116000_R33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1\u03b1 on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"2021122207503116000_R34","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"2021122207503116000_R35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.hoc.2007.08.009","article-title":"Pathophysiology of multiple myeloma bone disease","volume":"21","author":"Lentzsch","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122207503116000_R36","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1\u03b1 are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"2021122207503116000_R37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1634\/theoncologist.2008-0087","article-title":"Bone-resorbing cells in multiple myeloma: Osteoclasts, myeloma cell polykaryons, or both?","volume":"14","author":"Silvestris","year":"2009","journal-title":"The Oncologist"},{"key":"2021122207503116000_R38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"2021122207503116000_R39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00163574","article-title":"Myeloma affects both the growth and function of human osteoblast-like cells","volume":"10","author":"Evans","year":"1992","journal-title":"Clin Exp Metastasis"},{"key":"2021122207503116000_R40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"key":"2021122207503116000_R41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"2021122207503116000_R42","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","author":"Kawano","year":"2003","journal-title":"J Cell Sci"},{"key":"2021122207503116000_R43","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207503116000_R44","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122207503116000_R45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"2021122207503116000_R46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2008.01164.x","article-title":"Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment","volume":"82","author":"Heider","year":"2009","journal-title":"Eur J Haematol"},{"key":"2021122207503116000_R47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2007.12.006","article-title":"Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma","volume":"42","author":"Qiang","year":"2008","journal-title":"Bone"},{"key":"2021122207503116000_R48","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"2021122207503116000_R49","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"2021122207503116000_R50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2007.06665.x","article-title":"Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK","volume":"138","author":"Hecht","year":"2007","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R51","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V86.8.3151.3151","article-title":"Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin","volume":"86","author":"Barill\u00e9","year":"1995","journal-title":"Blood"},{"key":"2021122207503116000_R52","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"2021122207503116000_R53","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"2021122207503116000_R54","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"2021122207503116000_R55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: A role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"2021122207503116000_R57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejrad.2004.04.015","article-title":"Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: An alternative to conventional radiography","volume":"54","author":"Horger","year":"2005","journal-title":"Eur J Radiol"},{"key":"2021122207503116000_R58","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V90.6.2127","article-title":"Magnetic resonance imaging of the bone marrow in hematologic malignancies","volume":"90","author":"Moulopoulos","year":"1997","journal-title":"Blood"},{"key":"2021122207503116000_R59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-006-0184-3","article-title":"PET\/CT and MR imaging in myeloma","volume":"36","author":"Mulligan","year":"2007","journal-title":"Skeletal Radiol"},{"key":"2021122207503116000_R60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R62","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ejca.2005.11.034","article-title":"Bone markers in multiple myeloma","volume":"42","author":"Heider","year":"2006","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"2021122207503116000_R63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: Clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"The Oncologist"},{"key":"2021122207503116000_R64","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122207503116000_R65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R66","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"2021122207503116000_R67","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R68","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R69","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122207503116000_R70","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122207503116000_R71","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R72","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207503116000_R73","article-title":"Guidance for the use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network","volume-title":"Ann Oncol","author":"Terpos","year":"2009"},{"key":"2021122207503116000_R74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122207503116000_R75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122207503116000_R76","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"2021122207503116000_R77","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138161207780162908","article-title":"Proteasome as an emerging therapeutic target in cancer","volume":"13","author":"Zavrski","year":"2007","journal-title":"Curr Pharm Des"},{"key":"2021122207503116000_R78","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"key":"2021122207503116000_R79","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.17.6.879","article-title":"The potential of proteasome inhibitors in cancer therapy","volume":"17","author":"Sterz","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122207503116000_R80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122207503116000_R81","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.leukres.2008.02.019","article-title":"Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions","volume":"32","author":"Boissy","year":"2008","journal-title":"Leuk Res"},{"key":"2021122207503116000_R82","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00432-008-0461-8","article-title":"Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I-\u03baB kinase","volume":"135","author":"von Metzler","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122207503116000_R83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"2021122207503116000_R84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"2021122207503116000_R85","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"2021122207503116000_R86","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"key":"2021122207503116000_R87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"2021122207503116000_R88","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","article-title":"The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma","volume":"21","author":"Terpos","year":"2007","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2021122207503116000_R89","first-page":"169a","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma","volume":"110","author":"Fulciniti","year":"2007","journal-title":"Blood"},{"key":"2021122207503116000_R90","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-\u03baB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122207503116000_R91","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2008.127","article-title":"The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/3\/276\/41841139\/oncolo_14_3_276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/3\/276\/41841139\/oncolo_14_3_276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T09:32:18Z","timestamp":1640165538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/3\/276\/6397661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,3,13]]},"published-print":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0003","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,3,1]]},"published":{"date-parts":[[2009,3,1]]}}}